Home
causes
give
events
blog
donate
contact
FAQs & Resources
mission
history
stories
partners
2020 Cancer Grant
Recipients
previous recipients
Dr.
Alberto
Ciccia
2020
Associate Professor of Genetics & Development
Columbia University Irving Medical Center
Large-scale functional analysis of BRCA1/2 single nucleotide variants
Learn More
Dr.
Paul
Lambert
2020
Howard M. Temin Professor and Chair of Oncology
University of Wisconsin School of Medicine and Public Health
Role of the Microbiome in Cervical Cancer
Learn More
Dr.
Zhijie
Liu
2020
Assistant Professor, Molecular Medicine
The University of Texas Health Science Center at San Antonio
Targeting a non-canonical role of YAP/TEAD for breast cancer therapy
Learn More
Dr.
Liza
Makowski
2020
Professor, Department of Medicine
The University of Tennessee Health Science Center
PKC agonism reprograms innate immune suppression in Triple Negative Breast Cancer
Learn More
Dr.
Benjamin
Neel
2020
Professor, NYU Grossman School of Medicine/Director, Perlmutter Cancer Center
NYU Grossman School of Medicine
Genomics-Informed Organoid Platform for Rational Modeling of Ovarian Cancer Biology and Therapy.
Learn More
Dr.
Mark
Pegram
2020
Susy Yuan-Huey Hung Professor of Medical Oncology
Stanford University School of Medicine
Mechanisms of antibody-dependent cell-mediated cytotoxicity (ADCC) tolerance in HER2+ breast cancer
Learn More
Dr.
Richard
Wang
2020
Associate Professor, Dermatology
UT Southwestern Medical Center
Development of a novel marker for cervical cancer using HPV circular RNA
Learn More
Dr.
Karl
Willert
2020
Professor, Cellular & Molecular Medicine
University of California San Diego
Targeted Killing of FZD7-Positive Ovarian Tumors
Learn More
Dr.
Hua
Yu
2020
Associate Chair and Professor, Department of Immuno-Oncology
Beckman Research Institute of City of Hope
The opposing roles of PARP and PARG inhibitors in regulating ovarian cancer immune responses.
Learn More
Dr.
Hui
Zong
2020
Associate Professor, Microbiology, Immunology, & Cancer Biology
University of Virginia
Optimization of dosing regimen of PARP inhibitor for BRCA1-related breast cancer prevention.
Learn More
previous recipients
home
causes
give
events
blog
donate now